Info

Since 1994, the Helix3 team has specialized in developing protocols integrating the comet assay into the standard in vitro and in vivo tests required by regulatory agencies. These Helix3 innovations minimize the use of resources while maximizing the information obtained from a single study. Together, the Helix3 staff has conducted more GLP comet assay studies than anyone in the world. Their experience with new assay development, research, and conducting genetox studies all according to GLP guidelines has been the basis for collaborations with scientists worldwide to develop new techniques for mechanistic and efficacy research applications.